Market Cap
$8.6M
CMMB
Chemomab Therapeutics Ltd.
$1.30 ▲ +9.24%
Prev close $1.19Market cap$8.6M
12-mo target$5.00 (+249.7%)
High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on CMMB right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
5 funds
Inst. Value
$243.9K
Inst. Activity
2 buys / 0 sells
Insider Activity
$20.2K buy / $6.5K sell
Insider Net $
$13.7K
Social Sentiment
67° Warm
SEC Reports
7
Press Releases
1
Price chart 30d -54.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 28, 2026 Insider
Cohen Neil Harris sold 1,000 shares
Director @ $2.80 ($2.8K)
Aug 27, 2026 Insider
Aug 19, 2026 SEC Cohen Neil Harris sold 1,304 shares
Director @ $2.85 ($3.7K)
Chemomab reported Q2 2026 financial results and provided a corporate update centered on the proposed all-stock merger wi
6-K — Impact 6/10
Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs consensus of $0.00, with no revenue. The planned m
PRESS-RELEASE — Impact 6/10
Aug 19, 2026 earnings
Jul 8, 2026 SEC Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA
Chemomab Therapeutics (CMMB) entered into a definitive merger agreement to be acquired by Scipher Medicine Corporation,
6-K — Impact 7/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — ADD
95,311 shares ($154.4K)
Jun 30, 2026 Inst.
RHUMBLINE ADVISERS — ADD
30,529 shares ($49.5K)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 27, 2025 | Oppenheimer | MAINTAIN | Outperform | 52% |
| May 16, 2025 | Oppenheimer | MAINTAIN | Outperform | 52% |
| Feb 20, 2025 | Maxim Group | MAINTAIN | Buy | 43% |
| Nov 15, 2024 | Oppenheimer | REITERATE | Outperform | 52% |
| May 13, 2024 | Maxim Group | INITIATE | Buy | 43% |
| May 6, 2024 | Oppenheimer | UPGRADE | Outperform | 52% |
| Mar 8, 2024 | Oppenheimer | MAINTAIN | Perform | 52% |
| Oct 6, 2023 | Roth MKM | INITIATE | Buy | 52% |
| Jun 7, 2023 | Oppenheimer | DOWNGRADE | Perform | 52% |
| Apr 18, 2023 | Oppenheimer | MAINTAIN | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Aug 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jul 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% |
Price targets
Where 1 covering analysts think CMMB trades over the next 12 months.
$5.00 +249.7% upside Strong Buy
Current$1.43 Low$5.00 Median$5.00 High$5.00 1 analysts
$5.00$5.00
Analyst rating None as of Oct 3, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 1 bullish, 1 bearish, 0 mixed, 5 neutral · avg impact 4.6/10.Plus 1 press releases.
NEUTRAL6-K6/10
Chemomab reported Q2 2026 financial results and provided a corporate update centered on the proposed
Aug 19, 2026
BEARISHPRESS-RELEASE6/10
Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs consensus of $0.00, with no re
Aug 19, 2026
BULLISH6-K7/10
Chemomab Therapeutics (CMMB) entered into a definitive merger agreement to be acquired by Scipher Me
Jul 8, 2026
NEUTRAL6-K2/10
Chemomab Therapeutics appointed Gwen Melincoff as a new independent director and chair of the nomina
Jun 2, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 19, 2026
earnings
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA continues to advance with closing expected by yea
Aug 12, 2026
earnings_calendar
CMMB Q2 2026 Earnings Scheduled — 2026-08-12
Jul 6, 2026
Clinical Trial
CM-101 in PSC Patients -The SPRING Study
Phase Phase 2 — COMPLETED
May 14, 2026
earnings
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
Chemomab announced financial and operating results for the first quarter and provided a corporate update, including 4 presentations at DDW and EASL 20
May 13, 2026
earnings_calendar
CMMB Q1 2026 Earnings Scheduled — 2026-05-13
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | 100.0% | — | 1↑ 0↓ | $0.0B | 1 |
| Next Q | $0.00 | $0.00–$0.00 | 100.0% | — | 1↑ 0↓ | $0.0B | 1 |
| Current FY | $-0.02 | $-0.02–$-0.02 | -11.1% | +0.0% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $-0.03 | $-0.03–$-0.03 | -50.0% | +0.0% | 1↑ 0↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.000 | — |
| 7d ago | $0.000 | — |
| 30d ago | $0.000 | — |
| 60d ago | $-0.010 | +0.010 |
| 90d ago | $-0.010 | +0.010 |
Institutional ownership
Which big funds own CMMB (from quarterly 13F filings) and who is adding or trimming.
5 institutional holders with $243.9K total value (150,561 shares) as of 2026-Q2. Top holders: CITADEL, RHUMBLINE, Lido. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 95,311 | $154.4K | 63.3% | ADD +48.5% |
| RHUMBLINE ADVISERS | 30,529 | $49.5K | 20.3% | ADD +66.2% |
| Lido Advisors, LLC | 14,341 | $23.2K | 9.5% | — |
| BNP PARIBAS FINANCIAL MARKETS | 6,805 | $11.0K | 4.5% | ADD +41.3% |
| MORGAN STANLEY | 3,575 | $5.8K | 2.4% | NEAR_EXIT -95.8% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | ADD | 64,182 | 95,311 | +48.5% | $154.4K |
| RHUMBLINE ADVISERS | ADD | 18,366 | 30,529 | +66.2% | $49.5K |
| UBS Group AG | NEAR_EXIT | 2,253 | 8 | -99.6% | $13.00 |
| RHUMBLINE ADVISERS | ADD | 9,505 | 17,856 | +87.9% | $29.5K |
| JANE STREET GROUP, LLC | TRIM | 21,511 | 15,598 | -27.5% | $25.7K |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 5,750 | 8,125 | +41.3% | $13.4K |
| MORGAN STANLEY | NEAR_EXIT | 90,065 | 3,775 | -95.8% | $6.2K |
| UBS Group AG | DOUBLED | 99 | 2,253 | +2175.8% | $3.7K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
2 insiders, 13 transactions. Net $13.7K — $20.2K bought, $6.5K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Cohen Neil Harris | Director | SELL | 1,000 | $2.80 | $2.8K |
| Aug 27, 2026 | Cohen Neil Harris | Director | SELL | 1,304 | $2.85 | $3.7K |
| May 29, 2026 | Mor George Adi | Chief Executive Officer | BUY | 4,878 | $2.05 | $10.0K |
| May 29, 2026 | Mor George Adi | Chief Executive Officer | J | 31,712 | — | — |
| May 29, 2026 | Mor George Adi | Chief Executive Officer | BUY | 4,926 | $2.08 | $10.2K |
| May 29, 2026 | Mor George Adi | Chief Executive Officer | J | 18,750 | — | — |
| Mar 16, 2026 | Cohen Neil Harris | Director | AWARD | 5,172 | — | — |
| Mar 16, 2025 | Cohen Neil Harris | Director | AWARD | 3,821 | — | — |
| Mar 18, 2024 | Cohen Neil Harris | Director | AWARD | 2,520 | — | — |
| Mar 21, 2023 | Cohen Neil Harris | Director | AWARD | 1,714 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CMMB.
Shares short
81,947
Settlement Sep 15, 2026
Change vs prior
-20.2%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈1.1%
Estimate — not % of float
All CMMB filing & press-release reports (8)
- 6-K reportAug 19, 2026
- PRESS-RELEASE reportAug 19, 2026
- 6-K reportJul 8, 2026
- 6-K reportJun 2, 2026
- PRESS-RELEASE reportMay 14, 2026
- 6-K reportMay 14, 2026
- 6-K reportMay 6, 2026
- PRESS-RELEASE reportMar 19, 2026